Last updated: August 30, 2026
Eribulin mesylate, marketed by Eisai as Halaven, is a mature oncology product with declining branded revenue, established generic competition, and continuing demand in metastatic breast cancer and unresectable or metastatic liposarcoma. Its commercial profile is shifting from innovation-driven growth to lifecycle management, geographic expansion, and cost-sensitive injectable oncology access.
The product remains strategically relevant because it has a differentiated mechanism, two approved tumor indications, and no biosimilar exposure. Its main risks are generic price erosion, reduced use after multiple lines of therapy, competing antibody-drug conjugates, and the expiration of residual formulation and regulatory protections.
What is eribulin mesylate and how does it generate revenue?
Eribulin mesylate is the mesylate salt of eribulin, a synthetic analog of halichondrin B. It inhibits microtubule growth and is administered intravenously.
The U.S. Food and Drug Administration approved Halaven in 2010 for metastatic breast cancer previously treated with an anthracycline and a taxane. FDA expanded the label in 2016 to include unresectable or metastatic liposarcoma after prior anthracycline-containing therapy.[1]
The commercial product is concentrated in later-line oncology treatment, where sales depend on:
- Continued diagnosis of metastatic breast cancer and liposarcoma.
- Physician familiarity with intravenous chemotherapy.
- Reimbursement for hospital and outpatient infusion.
- Availability of generic eribulin injection.
- Relative performance against newer agents, including antibody-drug conjugates and targeted therapies.
- Eisai’s pricing and distribution strategy by country.
Eribulin does not have the broad first-line market of newer breast cancer agents. Its use is concentrated in patients who have progressed through prior treatments, limiting volume growth but preserving a clinically defined niche.
How has the financial trajectory of Halaven changed?
Halaven revenue has followed a mature-product decline. Eisai’s annual disclosures show that the product has moved from a meaningful global oncology franchise to a smaller established-brand contributor as generic entry and competitive substitution have increased.[2][3]
Financial trajectory
| Period |
Commercial position |
Revenue direction |
| 2010-2015 |
U.S. launch and breast cancer expansion |
Growth after FDA approval |
| 2016-2019 |
Liposarcoma label expansion and global commercial maturity |
Stabilization, then decline |
| 2020-2022 |
Generic approvals in major markets and COVID-19 treatment disruption |
Accelerating erosion |
| 2023-2025 |
Mature branded product with generic competition |
Continued decline and geographic price pressure |
Eisai has not positioned Halaven as a core growth driver in the same category as Lenvima or Leqembi. Its financial contribution is now small relative to Eisai’s principal growth products. The company’s annual reports identify Halaven as an established product whose sales are affected by generic competition and market maturity.[2][3]
The financial trajectory is therefore characterized by:
- Lower branded volume in the United States and other developed markets.
- Greater reliance on international markets where generic penetration is slower.
- Reduced pricing power in hospital procurement.
- Stable demand in selected later-line indications.
- Declining contribution to Eisai’s consolidated revenue and operating leverage.
Eribulin remains commercially useful, but its strategic value is greater than its likely future revenue growth. It provides an established oncology cash flow stream without requiring the development costs associated with a new molecular entity.
What are the principal market drivers for eribulin mesylate?
Metastatic breast cancer demand
Breast cancer is the larger addressable market. Eribulin is used after prior anthracycline- and taxane-based treatment, often in heavily pretreated patients.
Its demand is supported by:
- A large global breast cancer population.
- Continued treatment of metastatic disease over multiple lines.
- Clinical familiarity and established dosing.
- Use in patients who have exhausted or are unsuitable for targeted options.
- Availability as an intravenous therapy in oncology centers.
The market is constrained by the movement of treatment toward biomarker-selected therapies, oral medicines, and antibody-drug conjugates. Eribulin faces competition from capecitabine, vinorelbine, gemcitabine, taxanes, sacituzumab govitecan, trastuzumab deruxtecan, and other later-line regimens.
Liposarcoma demand
Liposarcoma is a smaller market but provides differentiation. Eribulin has an FDA-approved indication for unresectable or metastatic liposarcoma after prior anthracycline therapy.[1]
The indication benefits from:
- Limited systemic treatment options.
- Specialist use in sarcoma centers.
- The product’s randomized-study evidence in advanced liposarcoma.
- A more defensible niche than the broader breast cancer market.
The commercial limitation is market size. Liposarcoma does not create sufficient volume to offset broad generic erosion in breast cancer.
Hospital and infusion-channel economics
Eribulin is a sterile injectable product. Purchasing decisions are influenced by:
- Acquisition price.
- Contracting with group purchasing organizations.
- Availability of multiple generic suppliers.
- Buy-and-bill reimbursement.
- Drug wastage and vial utilization.
- Supply reliability.
Generic competition can reduce the reimbursement spread for providers, while supply disruptions can temporarily increase demand for branded or alternate generic suppliers.
When did eribulin lose key exclusivity protections?
The principal U.S. regulatory protections have expired or no longer prevent generic competition.
| Protection |
Approximate status |
| New chemical entity exclusivity |
Expired after the 2010 approval period |
| Breast cancer indication protection |
Expired before broad generic competition |
| Liposarcoma orphan-drug exclusivity |
Seven-year period ended in 2023 |
| U.S. composition and related patent protection |
Core protection expired before current generic market entry |
| Generic entry |
Began in the United States around 2019-2020 |
FDA approved the first generic versions of eribulin mesylate injection after the relevant brand protections no longer blocked abbreviated new drug applications.[4]
The exact commercial loss-of-exclusivity date differs by jurisdiction because patent term adjustments, pediatric extensions, national approvals, and local regulatory rules vary. The practical conclusion is consistent: Halaven is no longer protected by a meaningful global exclusivity barrier.
What patents protect eribulin mesylate and its formulations?
The original eribulin patent estate was based on halichondrin analog chemistry and related pharmaceutical compositions. Core composition protection has expired in the United States.
Patent categories
The historical estate included:
- Eribulin and related halichondrin analog compositions.
- Salt forms, including eribulin mesylate.
- Pharmaceutical compositions.
- Methods of treating cancer.
- Synthetic and manufacturing processes.
- Crystalline or formulation-related claims in selected jurisdictions.
The remaining commercial value of these patents is limited because generic manufacturers have already obtained regulatory approvals in major markets. Later-filed formulation or manufacturing patents would need to create a genuine regulatory or technical barrier to materially delay entry. Available evidence does not indicate a current U.S. patent barrier comparable to the estate surrounding newer oncology products.
How strong is the eribulin patent estate?
The estate is commercially weak for exclusivity purposes and moderately relevant for manufacturing know-how.
| Criterion |
Assessment |
| Core composition protection |
Expired or commercially exhausted |
| Method-of-use protection |
Limited practical blocking power |
| Formulation protection |
Not a major current barrier |
| Manufacturing complexity |
Moderate to high |
| Generic regulatory barrier |
Low to moderate |
| Litigation leverage |
Limited after generic approvals |
| Long-term brand protection |
Low |
Eribulin’s chemical synthesis is technically complex because the molecule contains multiple stereocenters and a macrocyclic structure. That complexity can raise API-development and quality-control costs. It does not, however, prevent generic entry once an applicant has developed a reproducible route and validated sterile manufacturing.
What is the Orange Book status of Halaven?
Halaven is listed in FDA’s Orange Book as a prescription injectable product approved under NDA 201532.[5] The Orange Book records patent and exclusivity information relevant to approved drug products and generic approval pathways.
The practical Orange Book position is:
- Halaven remains the reference listed drug for U.S. generic applications.
- Generic applicants may rely on the reference product through an ANDA.
- Paragraph IV certifications were relevant during the original generic filing process.
- Expired or nonblocking patents no longer provide a durable barrier to approval.
- Current competition is primarily a price, supply, and contracting issue.
Because Orange Book listings can change with patent delistings, corrections, and regulatory updates, transaction or litigation analysis should use the current FDA record rather than historical listings alone.
Which companies are challenging Halaven with generic products?
The U.S. generic market includes multiple approved or commercialized eribulin mesylate injection suppliers. Companies associated with generic eribulin approvals or market participation have included Teva, Dr. Reddy’s Laboratories, and other ANDA holders.[4][6]
The competitive structure is fragmented:
| Competitor type |
Commercial effect |
| Large multinational generic companies |
Increase contracting pressure and national coverage |
| Indian generic manufacturers |
Add price competition and manufacturing capacity |
| Authorized or branded channels |
Preserve some higher-price demand |
| Regional injectable suppliers |
Exploit hospital shortages and local tenders |
| Eisai brand |
Retains physician recognition and supply reliability |
Generic competition is likely to produce larger discounts in the United States than in markets where procurement is centralized or generic substitution is slower. Injectable oncology products can also experience temporary supply constraints, allowing a branded product to retain limited demand even after patent expiry.
What Paragraph IV challenges affected eribulin?
Paragraph IV certifications are the standard U.S. mechanism through which an ANDA applicant asserts that listed patents are invalid, unenforceable, or not infringed. Generic eribulin applicants used the ANDA pathway after the relevant Halaven exclusivity period ended.[4][5]
The commercial significance of the challenges was greater during the pre-entry period than after approval. Once multiple generic products entered, the market shifted from patent litigation risk to:
- Price competition.
- Generic allocation.
- Hospital formulary preference.
- Supply continuity.
- Reimbursement economics.
Publicly available information does not indicate a current, market-blocking Paragraph IV dispute that would restore Halaven exclusivity.
What litigation and settlement agreements affect eribulin?
Eribulin has had a lower-profile U.S. patent litigation environment than high-revenue oncology products with extensive secondary patent estates. The critical legal event was the transition from patent-protected branded sales to ANDA-based generic competition.
No major current settlement agreement appears to provide a durable commercial extension for Halaven in the United States. Any historic generic settlements would need to be reviewed against the specific defendant, patent, entry date, and jurisdiction because settlement terms can vary significantly.
The absence of a current blocking settlement means that future commercial outcomes will be determined primarily by generic supplier behavior and demand rather than by a delayed-entry agreement.
What FDA regulatory status does eribulin have?
Eribulin mesylate has full FDA approval for:
- Metastatic breast cancer in patients who previously received an anthracycline- and taxane-based regimen.
- Unresectable or metastatic liposarcoma in patients who previously received an anthracycline-containing regimen.[1]
It is not a biologic and does not face biosimilar competition. Its generic pathway is the ANDA route, not the 351(k) biosimilar pathway.
Regulatory advantages include:
- A long-established safety database.
- Defined dosing and administration.
- A recognized reference product.
- Generic approval precedent.
- No requirement to establish a new clinical benefit for each ANDA applicant.
Regulatory risks include manufacturing deviations, sterile injectable quality failures, and supply interruptions. These risks can affect short-term market share even when patents no longer restrict entry.
How does eribulin compare with competing oncology drugs?
| Product |
Main differentiation |
Competitive position versus eribulin |
| Eribulin |
Microtubule inhibitor; breast cancer and liposarcoma labels |
Mature injectable, low-cost later-line option |
| Capecitabine |
Oral fluoropyrimidine |
Greater convenience and broad use |
| Vinorelbine |
Established chemotherapy |
Competes in later-line breast cancer |
| Sacituzumab govitecan |
Antibody-drug conjugate |
Higher innovation and price; competes in advanced breast cancer |
| Trastuzumab deruxtecan |
HER2-directed antibody-drug conjugate |
Stronger position in biomarker-defined disease |
| Taxanes |
Broad chemotherapy use |
Overlap in breast cancer, but prior treatment can limit reuse |
| Gemcitabine |
Broad cytotoxic use |
Competes in multiple solid tumors |
Eribulin’s advantage is cost and familiarity. Its disadvantage is the lack of biomarker-driven differentiation and the burden of intravenous treatment.
What generic entry risks exist for Halaven?
The main generic entry risks are already realized rather than pending.
Price erosion
Multiple suppliers generally reduce average selling price. The erosion is most severe where:
- Pharmacy benefit managers or hospital systems conduct competitive tenders.
- Generic substitution is automatic.
- Several approved suppliers maintain reliable supply.
- The reference product has no unique delivery feature.
Volume migration
Physicians and hospitals may convert patients to generic eribulin without changing treatment protocols. This causes direct brand-volume loss rather than therapeutic substitution.
Therapeutic substitution
Newer agents can reduce total eribulin demand, particularly in breast cancer patients with actionable biomarkers or access to antibody-drug conjugates.
Supply-driven volatility
Sterile injectable manufacturing is vulnerable to site shutdowns, quality investigations, and capacity constraints. A shortage can temporarily support branded demand, but it does not create durable pricing power.
What geographic markets remain attractive for eribulin?
The United States is a mature, highly competitive market. Japan and other developed Asian markets remain important because Eisai has strong regional infrastructure and established oncology relationships. Europe is shaped by national reimbursement, tendering, and generic substitution.
Emerging markets may offer volume growth, but revenue quality is lower because of:
- Lower prices.
- Local procurement requirements.
- Currency volatility.
- Parallel trade.
- Local generic manufacturing.
- Uneven reimbursement.
The most attractive markets are those with:
- Recognized metastatic breast cancer treatment pathways.
- Reimbursement for hospital-administered oncology drugs.
- Limited access to newer high-cost alternatives.
- Reliable distribution and sterile injectable supply.
- Lower generic penetration or delayed tender pressure.
Geographic expansion can slow revenue decline, but it is unlikely to restore the growth profile seen after the original U.S. launch.
Does eribulin have biosimilar risk?
No. Eribulin is a chemically synthesized small molecule, not a biologic. Biosimilar competition under the FDA 351(k) pathway is therefore irrelevant.
The relevant competitive risks are generic eribulin products and therapeutic alternatives. This distinction matters for valuation because generic entry can be faster and more price-destructive than biosimilar entry, while clinical switching is usually simpler for a small-molecule injectable.
What manufacturing and intellectual-property barriers remain?
The principal residual barrier is technical execution rather than patent exclusivity.
Generic manufacturers must address:
- Complex chemical synthesis.
- Stereochemical control.
- API impurity profiles.
- Salt formation and stability.
- Sterile injectable production.
- Container-closure integrity.
- Consistent vial filling.
- Comparable product quality and bioequivalence.
These requirements can limit the number of reliable suppliers, but they do not create a durable monopoly. Companies with established oncology-injectable facilities have a structural advantage over smaller entrants.
For Eisai, manufacturing know-how may protect supply quality and brand reputation. It is unlikely to prevent generic substitution where approved alternatives are available.
What is the likely financial outlook for eribulin through 2030?
The base case is continued low-single-digit to mid-single-digit annual revenue erosion in developed markets, offset in part by emerging-market volume and periodic supply disruptions among generic competitors.
Base-case outlook
| Driver |
Expected effect |
| U.S. generic penetration |
Strong negative |
| European tendering |
Negative |
| Liposarcoma niche |
Stabilizing but too small to drive growth |
| Breast cancer incidence |
Supports underlying demand |
| Newer targeted therapies |
Negative |
| Emerging-market expansion |
Moderate positive |
| Injectable shortages |
Temporary positive |
| Brand price increases |
Limited by reimbursement and competition |
A sharper decline is possible if generic suppliers maintain reliable supply and oncology practices rapidly replace eribulin with antibody-drug conjugates. A slower decline is possible if generic shortages persist or if cost containment favors established chemotherapy over newer high-price products.
Eribulin is unlikely to become a growth asset for Eisai without a new formulation, combination strategy, additional high-value indication, or commercial partnership. Its most probable role is a declining but durable specialty-oncology product.
How should investors and licensing teams value eribulin?
Eribulin should be valued as a mature cash-flow asset, not as a pipeline-like growth product.
Key diligence variables include:
- Net sales by country.
- Brand versus generic market share.
- Average realized price.
- Eisai’s manufacturing cost.
- Generic supplier count.
- FDA shortage records.
- Hospital tender outcomes.
- Liposarcoma treatment volume.
- Reimbursement changes.
- Patent and regulatory status by country.
- Any future combination or formulation development.
A licensing transaction would require a low acquisition price or a clear geographic advantage. The strongest rationale would be distribution in underpenetrated markets, reliable sterile manufacturing, or a cost-efficient generic platform. A transaction based only on historical Halaven revenue would carry substantial downside risk.
Key Takeaways
- Eribulin mesylate is a mature injectable oncology product marketed by Eisai as Halaven.
- Its FDA-approved indications are metastatic breast cancer and unresectable or metastatic liposarcoma.
- Core exclusivity has expired, and generic competition is established in the United States and other major markets.
- The product has no biosimilar risk because eribulin is a synthetic small molecule.
- Revenue is declining as generic substitution, price pressure, and newer oncology therapies reduce branded demand.
- Liposarcoma provides clinical differentiation but is too small to offset broad breast cancer erosion.
- Complex synthesis and sterile manufacturing create execution barriers, not a durable patent monopoly.
- The likely financial profile through 2030 is declining specialty-oncology cash flow with limited growth prospects.
- The main commercial variables are generic supply, hospital contracting, geographic pricing, and therapeutic substitution.
FAQs about eribulin mesylate market dynamics
Is Halaven still commercially available after generic eribulin approval?
Yes. Halaven remains the reference branded product, but generic eribulin mesylate injection competes in major markets and has reduced the brand’s pricing and volume power.
Can eribulin mesylate sales recover through a new cancer indication?
A new indication could expand demand, but the economic benefit would depend on regulatory exclusivity, clinical differentiation, reimbursement, and the ability to overcome established generic competition.
What makes eribulin different from a taxane?
Eribulin is a halichondrin B analog that inhibits microtubule growth through a mechanism distinct from taxane stabilization. It is used after prior exposure to anthracyclines and taxanes in its approved indications.
Does eribulin mesylate face competition from oral cancer drugs?
Yes. Oral agents such as capecitabine compete with intravenous eribulin on convenience, administration burden, and treatment flexibility, although patient suitability and prior treatment history determine actual use.
Is eribulin mesylate a viable generic manufacturing opportunity?
It can be viable for manufacturers with complex-API capabilities and sterile injectable capacity. The opportunity is constrained by generic price erosion, established suppliers, regulatory compliance costs, and hospital contracting pressure.
References
- U.S. Food and Drug Administration. (2016). FDA approves Halaven for advanced liposarcoma. https://www.fda.gov
- Eisai Co., Ltd. (2024). Integrated report 2024. https://www.eisai.com
- Eisai Co., Ltd. (2023). Annual report 2023. https://www.eisai.com
- U.S. Food and Drug Administration. (2020). FDA approves first generic eribulin mesylate injection. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
- Drugs@FDA. (2024). Eribulin mesylate injection approval records. U.S. Food and Drug Administration. https://www.accessdata.fda.gov
